Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Subjects With Advanced Melanoma Failing Front-line Treatment With Checkpoint Inhibitors (CPI) or TNBC Failing Front-line Chemotherapy for Metastatic Disease

Next Previous
X
Search
Trial Profile

A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Subjects With Advanced Melanoma Failing Front-line Treatment With Checkpoint Inhibitors (CPI) or TNBC Failing Front-line Chemotherapy for Metastatic Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Odetiglucan (Primary) ; Pembrolizumab (Primary)
  • Indications Advanced breast cancer; Malignant melanoma; Triple negative breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms IMPRIME-1
  • Sponsors Biothera; HiberCell

    • Most Recent Events

    • 23 Mar 2021 Status changed from active, no longer recruiting to completed.
    • 28 Apr 2020 Results presented at the 111th Annual Meeting of the American Association for Cancer Research - I.
    • 11 Dec 2019 Acording to a Biothera Pharmaceuticals media release, data from a primary analysis of this study was presented during a Spotlight Session at the 2019 San Antonio Breast Cancer Symposium (SABCS).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top